# Phase 3 Clinical Study of AK112 for NSCLC Patients

> **NCT05184712** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Akeso** · enrollment: 322 (actual)

## Conditions studied

- Non-Squamous Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Ivonescimab (SMT112 or AK112) Injection
- **DRUG:** Placebo Injection

## Key facts

- **NCT ID:** NCT05184712
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-25
- **Primary completion:** 2023-03-10
- **Final completion:** 2026-09
- **Target enrollment:** 322 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05184712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05184712, "Phase 3 Clinical Study of AK112 for NSCLC Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05184712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*